Is Medexus Pharmaceuticals Inc. (MEDXF) a Buy, Sell, or Hold?
OTC : MEDXF
Medexus Pharmaceuticals Inc.
$3.79 USD
$0.23 (6.46%)
- Volume
- 5.4K
- Average Volume
- 14.1K
- Market Capitalization
- $119.99M
- P/E Ratio
- -49.09
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $3.88
- Year Low
- $1.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.19
Company Overview
OTC
Kenneth d'Entremont
Drug Manufacturers - Specialty & Generic
Healthcare
MEDXF
90
CA
USD
Liquidity Metrics
0.45
1.19
0.57
0.12
0.00
Sales & Valuation
$99.33M
1.21
2.49
32.38
0.12
Profitability
-$0.07
-$2.39M
-2.41%
-2.28%
-4.64%
-1.63%
P/E Metrics
-49.09
1.11
1.11
Analyst Price Target & Rating
$7.00
$7.00
$7.00
2/5
1 Analysts
-45.86%
Financial Health Scores
1.18
4/9
$10.2M
$147.28M
$98.29M
$2.93M
Key Metrics (TTM)
$128.45M
1.29
10.20
1.19
-4.64%
5.82%
-2.10%
3.30%
258 days
Company Executives
| Name | Title |
|---|---|
| Brendon Buschman | Chief Financial Officer |
| Bill Poncy | Senior Vice President of Commercial Operations - United States |
| Tina Byers | Executive of Investor Relations |
| Richard Labelle | Chief Operating Officer |
| Brian Peters | Vice President of Sales & Marketing - United States |
| Ian C. Wildgoose Brown | General Counsel & Corporate Secretary |
| Kenneth d'Entremont | Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Medexus Pharmaceuticals Inc. (OTC:MEDXF) Stock
Medexus Pharmaceuticals Inc. is a specialized pharmaceutical firm conducting operations across both Canada and the United States. The company's therapeutic focus spans several critical domains, including cancer treatment (oncology), blood disorders (hematology), joint and muscle conditions (rheumatology), autoimmune disorders, and allergic reactions. Among its leading offerings are Rasuvo and Metoject, both methotrexate formulations specifically developed for managing rheumatoid arthritis and various autoimmune conditions. Another significant product is IXINITY, an intravenous recombinant factor IX therapy prescribed for individuals aged 12 and above suffering from Hemophilia B. Additionally, Rupall serves as a prescription medication for allergies. The company's diverse product lineup fur ... ther comprises Treosulfan, a bifunctional alkylating agent utilized in allogeneic hematopoietic stem cell transplants; Trispan, an injectable suspension of triamcinolone hexacetonide; and Gleolan, an optical imaging agent indicated for patients presenting with symptoms of glioma. Previously known as Pediapharm Inc., the company adopted its current name, Medexus Pharmaceuticals Inc., in December 2018. Its corporate headquarters are situated in Bolton, Canada.
2026-08-10 17:30:00
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 10, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, 2026 (the Company's fiscal Q1 2027). All dollar amounts in this news release are in US dollars unless specified otherwise.
Medexus Schedules First Fiscal Quarter 2027 Conference Call
2026-07-30 17:30:00
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 11, 2026 to discuss Medexus's results for its first fiscal quarter ended June 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on August 10, 2026.
2026-06-25 18:00:00
Management to host conference call at 8:00 AM Eastern time on Friday, June 26, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise.
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
2026-06-16 17:30:00
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026.
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
2026-06-09 17:30:00
UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro® (dorocubicel) Securing Canadian rights to a proprietary advanced clinical-stage product candidate developed in Canada adds to Medexus's medium-term product pipeline and helps build a North American allo-HSCT franchise Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 9, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company has secured exclusive Canadian rights to commercialize UM171 Cell Therapy, a proprietary advanced clinical stage investigational drug product that recently received conditional marketing authorization in Europe from the European Commission (or EC) as Zemcelpro® (dorocubicel), in a license and supply deal with ExCellThera, a blood stem cell expansion and metabolic fitness company, and Cordex Biologics, its wholly owned subsidiary. Zemcelpro® is a novel personalized cryopreserved hematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.
Frequently Asked Questions
-
What is the current Medexus Pharmaceuticals Inc. (MEDXF) stock price?
-
Medexus Pharmaceuticals Inc.(OTC:MEDXF) stock price is $3.79 in the last trading session. During the trading session, MEDXF stock reached the peak price of $3.88 while $1.8 was the lowest point it dropped to. The percentage change in MEDXF stock occurred in the recent session was 6.46% while the dollar amount for the price change in MEDXF stock was $0.23.
-
MEDXF's industry and sector of operation?
-
The OTC listed MEDXF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of MEDXF?
-
Brendon Buschman | Chief Financial Officer
Bill Poncy | Senior Vice President of Commercial Operations - United States
Tina Byers | Executive of Investor Relations
Richard Labelle | Chief Operating Officer
Brian Peters | Vice President of Sales & Marketing - United States -
How many employees does MEDXF have?
-
Number of MEDXF employees currently stands at 90. MEDXF operates from 10 King Street East, Toronto, ON M5C 1C3, CA.
-
Link for MEDXF official website?
-
Official Website of MEDXF is: https://www.medexus.com
-
How do I contact MEDXF?
-
MEDXF could be contacted at phone #877 633 3987 and can also be accessed through its website. MEDXF operates from 10 King Street East, Toronto, ON M5C 1C3, CA.
-
How many shares of MEDXF are traded daily?
-
The average number of MEDXF shares traded daily for last 3 months was 14.1K.
-
What is the market cap of MEDXF currently?
-
The market value of MEDXF currently stands at $119.99M with its latest stock price at $3.79